STOCK TITAN

Paragon 28, Inc. - $FNA STOCK NEWS

Welcome to our dedicated page for Paragon 28 news (Ticker: $FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Paragon 28's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Paragon 28's position in the market.

Rhea-AI Summary
Paragon 28, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences earnings
-
Rhea-AI Summary
Paragon 28 received FDA approval for a feasibility study on the SMART Total Talus System, which aims to improve patient outcomes and expand options for ankle replacement candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
conferences
Rhea-AI Summary
Paragon 28 (NYSE: FNA) Reports Strong Financial Results and Reaffirms 2023 Net Revenue Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
-
Rhea-AI Summary
Paragon 28 reports Q1 2023 financial results with record net revenue of $52.0 million and reaffirms 2023 net revenue guidance of $214-218 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
Paragon 28, Inc.

NYSE:FNA

FNA Rankings

FNA Stock Data

671.91M
39.20M
40.06%
49.64%
2.93%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ENGLEWOOD

About FNA

paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen